Teleflex secures 510(k) clearance to market Arrow JACC with Chlorag+ard Technology and TightTrack tunneler

10 October 2016 (Last Updated October 10th, 2016 18:30)

Teleflex, a provider of medical devices for critical care and surgery, has secured FDA 510(k) clearance to market its Arrow JACC with Chlorag+ard Technology and TightTrack tunneler.

Teleflex, a provider of medical devices for critical care and surgery, has secured FDA 510(k) clearance to market its Arrow JACC with Chlorag+ard Technology and TightTrack tunneler.

Arrow JACC with Chlorag+ard Technology is a long-term, tunneled, small french size antithrombogenic and antimicrobial central venous catheter intended to meet the requirements of patients throughout their course of therapy or illness.

Teleflex vascular division president Jay White said: “At Teleflex, we are committed to providing the right line for the right patient at the right time.

"This device enables caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients."

“We are proud to add the tunneled Arrow JACC to our line of vascular access products.

“By providing an antithromogenic and antimicrobial catheter that protects against catheter occlusion, we are offering a technology that no one else can.

“This is especially important in patients with end stage renal disease where vessel health and preservation is essential to provide a future dialysis vascular access.”

Further, the catheter is also meant for use with high-pressure injection for diagnostic studies.

The Arrow JACC with Chlorag+ard Technology protects against catheter occlusion, phlebitis, and intimal hyperplasia for up to 30 days.

This device enables caregivers to effectively and economically preserve vessel access, and care for millions of end stage renal disease patients.